SCYX
Price
$0.60
Change
+$0.02 (+3.45%)
Updated
Nov 19, 01:57 PM (EDT)
Capitalization
24.32M
133 days until earnings call
Intraday BUY SELL Signals
SIGA
Price
$5.88
Change
-$0.09 (-1.51%)
Updated
Nov 19, 02:00 PM (EDT)
Capitalization
427.52M
Intraday BUY SELL Signals
Interact to see
Advertisement

SCYX vs SIGA

Header iconSCYX vs SIGA Comparison
Open Charts SCYX vs SIGABanner chart's image
SCYNEXIS
Price$0.60
Change+$0.02 (+3.45%)
Volume$7.29K
Capitalization24.32M
SIGA Technologies
Price$5.88
Change-$0.09 (-1.51%)
Volume$225
Capitalization427.52M
SCYX vs SIGA Comparison Chart in %
SCYX
Daily Signal:
Gain/Loss:
SIGA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
SCYX vs. SIGA commentary
Nov 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCYX is a Hold and SIGA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 19, 2025
Stock price -- (SCYX: $0.58 vs. SIGA: $5.97)
Brand notoriety: SCYX and SIGA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: SCYX: 72% vs. SIGA: 98%
Market capitalization -- SCYX: $24.32M vs. SIGA: $427.52M
SCYX [@Pharmaceuticals: Generic] is valued at $24.32M. SIGA’s [@Pharmaceuticals: Generic] market capitalization is $427.52M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCYX’s FA Score shows that 0 FA rating(s) are green whileSIGA’s FA Score has 3 green FA rating(s).

  • SCYX’s FA Score: 0 green, 5 red.
  • SIGA’s FA Score: 3 green, 2 red.
According to our system of comparison, SIGA is a better buy in the long-term than SCYX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCYX’s TA Score shows that 5 TA indicator(s) are bullish while SIGA’s TA Score has 4 bullish TA indicator(s).

  • SCYX’s TA Score: 5 bullish, 3 bearish.
  • SIGA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SCYX is a better buy in the short-term than SIGA.

Price Growth

SCYX (@Pharmaceuticals: Generic) experienced а -3.56% price change this week, while SIGA (@Pharmaceuticals: Generic) price change was -5.09% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.85%. For the same industry, the average monthly price growth was -6.63%, and the average quarterly price growth was +28.06%.

Reported Earning Dates

SCYX is expected to report earnings on Apr 01, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.85% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SIGA($428M) has a higher market cap than SCYX($24.3M). SIGA has higher P/E ratio than SCYX: SIGA (5.80) vs SCYX (0.91). SIGA YTD gains are higher at: 9.700 vs. SCYX (-52.107). SIGA has higher annual earnings (EBITDA): 102M vs. SCYX (-19.29M). SIGA has more cash in the bank: 182M vs. SCYX (44.8M). SIGA has less debt than SCYX: SIGA (570K) vs SCYX (2.39M). SIGA has higher revenues than SCYX: SIGA (180M) vs SCYX (3.26M).
SCYXSIGASCYX / SIGA
Capitalization24.3M428M6%
EBITDA-19.29M102M-19%
Gain YTD-52.1079.700-537%
P/E Ratio0.915.8016%
Revenue3.26M180M2%
Total Cash44.8M182M25%
Total Debt2.39M570K419%
FUNDAMENTALS RATINGS
SCYX vs SIGA: Fundamental Ratings
SCYX
SIGA
OUTLOOK RATING
1..100
5954
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
2
Undervalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9521
PRICE GROWTH RATING
1..100
8965
P/E GROWTH RATING
1..100
9827
SEASONALITY SCORE
1..100
28n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SIGA's Valuation (2) in the Pharmaceuticals Other industry is somewhat better than the same rating for SCYX (44). This means that SIGA’s stock grew somewhat faster than SCYX’s over the last 12 months.

SIGA's Profit vs Risk Rating (93) in the Pharmaceuticals Other industry is in the same range as SCYX (100). This means that SIGA’s stock grew similarly to SCYX’s over the last 12 months.

SIGA's SMR Rating (21) in the Pharmaceuticals Other industry is significantly better than the same rating for SCYX (95). This means that SIGA’s stock grew significantly faster than SCYX’s over the last 12 months.

SIGA's Price Growth Rating (65) in the Pharmaceuticals Other industry is in the same range as SCYX (89). This means that SIGA’s stock grew similarly to SCYX’s over the last 12 months.

SIGA's P/E Growth Rating (27) in the Pharmaceuticals Other industry is significantly better than the same rating for SCYX (98). This means that SIGA’s stock grew significantly faster than SCYX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCYXSIGA
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 27 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
SCYX
Daily Signal:
Gain/Loss:
SIGA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FWOZX18.92N/A
N/A
Fidelity Advisor Women's Leadership Z
USAWX34.09N/A
N/A
Victory Sustainable World
HIGUX22.12N/A
N/A
Carillon Eagle Growth & Income R6
AXMNX15.64N/A
N/A
Acclivity Mid Cap Multi-Style N
JSEAX22.05-0.27
-1.21%
JPMorgan International Equity A

SCYX and

Correlation & Price change

A.I.dvisor tells us that SCYX and ELAN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+0.38%
ELAN - SCYX
29%
Poorly correlated
-0.14%
CRDL - SCYX
28%
Poorly correlated
+5.10%
ACET - SCYX
27%
Poorly correlated
+1.31%
EBS - SCYX
26%
Poorly correlated
+0.20%
SIGA - SCYX
26%
Poorly correlated
+1.19%
More

SIGA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SIGA has been loosely correlated with EBS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SIGA jumps, then EBS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SIGA
1D Price
Change %
SIGA100%
+1.19%
EBS - SIGA
41%
Loosely correlated
+0.20%
COLL - SIGA
28%
Poorly correlated
-0.07%
HROW - SIGA
26%
Poorly correlated
-1.56%
CRRTF - SIGA
26%
Poorly correlated
N/A
SCYX - SIGA
26%
Poorly correlated
+0.38%
More